Abbott Laboratories (NYSE:ABT) Stock Price Target Cut by BTIG Research

Key Points

• BTIG Research cut Abbott’s price target from $134 to $125 but maintained a “buy” rating, implying roughly 24% upside from the stock’s reported $100.59 price.
• Analyst sentiment remains positive overall: Abbott has a “Moderate Buy” consensus rating and an average price target of $118.60, supported by 24 Buy or Strong Buy ratings versus four Holds.
• Abbott’s latest quarter showed $1.42 adjusted EPS and $13.01 billion in revenue, with sales up 14.5% year over year; however, the company lowered its 2026 sales-growth outlook because of weakness in medical devices.

Abbott Laboratories (NYSE:ABT - Get Free Report) had its price target reduced by equities researchers at BTIG Research from $134.00 to $125.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has a "buy" rating on the healthcare product maker's stock. BTIG Research's price target indicates a potential upside of 24.27% from the stock's current price.

A number of other brokerages have also recently commented on ABT. UBS Group reduced their price target on shares of Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating on the stock in a research report on Tuesday, July 28th. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $130.00 price target on shares of Abbott Laboratories in a research report on Friday, July 17th. Barclays started coverage on Abbott Laboratories in a report on Wednesday, October 7th. They issued an "overweight" rating and a $120.00 price objective for the company. Wells Fargo & Company lifted their price objective on Abbott Laboratories from $109.00 to $112.00 and gave the stock an "overweight" rating in a research report on Friday, July 17th. Finally, Wolfe Research raised Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 target price on the stock in a research note on Thursday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat, Abbott Laboratories has a consensus rating of "Moderate Buy" and an average target price of $118.60.

Abbott Laboratories Price Performance

ABT stock opened at $100.59 on Thursday. The firm has a 50 day simple moving average of $105.47 and a two-hundred day simple moving average of $98.28. The stock has a market cap of $174.06 billion, a PE ratio of 32.55, a P/E/G ratio of 1.90 and a beta of 0.59. Abbott Laboratories has a one year low of $81.97 and a one year high of $132.02. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, meeting analysts' consensus estimates of $1.42. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%. The business had revenue of $13.01 billion for the quarter, compared to analysts' expectations of $12.99 billion. During the same quarter in the prior year, the firm earned $1.30 earnings per share. The firm's revenue was up 14.5% on a year-over-year basis. On average, analysts predict that Abbott Laboratories will post 5.53 EPS for the current fiscal year.

Hedge Funds Weigh In On Abbott Laboratories

Institutional investors have recently bought and sold shares of the stock. Parkway Wealth Management Group LLC boosted its position in Abbott Laboratories by 3.2% during the 3rd quarter. Parkway Wealth Management Group LLC now owns 3,208 shares of the healthcare product maker's stock valued at $317,000 after acquiring an additional 98 shares in the last quarter. St. Johns Investment Management Company LLC raised its position in shares of Abbott Laboratories by 1.0% in the 2nd quarter. St. Johns Investment Management Company LLC now owns 9,859 shares of the healthcare product maker's stock worth $895,000 after acquiring an additional 101 shares in the last quarter. AA Financial Advisors LLC lifted its stake in shares of Abbott Laboratories by 1.7% in the 3rd quarter. AA Financial Advisors LLC now owns 6,186 shares of the healthcare product maker's stock valued at $611,000 after purchasing an additional 101 shares during the period. Eagle Bay Advisors LLC lifted its stake in shares of Abbott Laboratories by 1.2% in the 3rd quarter. Eagle Bay Advisors LLC now owns 8,448 shares of the healthcare product maker's stock valued at $835,000 after purchasing an additional 102 shares during the period. Finally, Richards Merrill & Peterson Inc. boosted its position in shares of Abbott Laboratories by 1.1% during the third quarter. Richards Merrill & Peterson Inc. now owns 9,562 shares of the healthcare product maker's stock valued at $945,000 after purchasing an additional 102 shares in the last quarter. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott reported third-quarter adjusted earnings of $1.42 per share, matching the consensus estimate, while revenue increased 14.5% year over year to $13.01 billion, slightly above the $12.99 billion forecast. Comparable sales grew 7%, and the company reaffirmed its full-year adjusted EPS guidance. Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
• Positive Sentiment: Management announced a tax-free spin-off of its global Nutrition business, which includes brands such as Ensure, Similac, PediaSure, Glucerna and Pedialyte. Abbott expects the transaction to create two more focused companies, potentially accelerating Abbott’s sales growth and expanding its margin profile. Completion is targeted for the end of 2027. Abbott Nutrition Spin-Off Announcement
• Positive Sentiment: New product approvals and the European CE Mark for Abbott’s Cologuard Plus colorectal cancer test broaden the company’s diagnostics opportunity and could support longer-term growth. Abbott Secures Europe CE Mark for Colorectal Cancer Test
• Neutral Sentiment: The planned separation involves a nutrition operation generating approximately $8.5 billion in annual sales. While it may unlock value, investors will need to assess the eventual ownership structure, costs, tax implications and execution risks before determining whether the move improves shareholder returns. Abbott to Carve Out Nutrition Business
• Negative Sentiment: Abbott lowered its 2026 sales-growth outlook, citing weakness in medical devices. That guidance reduction overshadowed revenue growth and the reaffirmed EPS outlook, raising concerns about near-term demand and the company’s valuation. Abbott Lowers 2026 Sales Growth Forecast
• Negative Sentiment: Although adjusted EPS met the broad consensus, it was below the $1.43 estimate tracked by Zacks. The modest earnings shortfall, combined with the lower sales outlook, contributed to the stock’s decline despite higher revenue and expanding margins. Abbott Misses Q3 Earnings Estimates

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women's health and cardiometabolic care.

The company's nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.